Markus Joerger

Markus Joerger

Auto-generated profile, based on publicly available information

Markus Joerger

Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2005 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MJM. Joerger
M. Joerger
AHA. D. R. Huitema
A. D. R. Huitema
HBH. J. G. Desiree Van Den Bongard
H. J. G. Desiree Van Den Bongard
PBP. Baas
P. Baas
JSJ. H. Schornagel
J. H. Schornagel
JBJ. H. Beijnen
J. H. Beijnen
Aims: To characterize determinants of the elimination of methotrexate (MTX) and 7‐hydroxy‐methotrexate (7‐OH‐MTX) in patients receiving high‐dose MTX therapy (HDMTX).Methods: 24 and 48‐h blood samples from 76 patients receiving HDMTX (dose range 300 mg m−2 to 12 g m−2) were analysed, and concentration‐time data were subjected to population pharmacokinetic and covariate analysis using nonlinear mixed‐effect modelling (NONMEM).Results: Treatment‐related mortality was 1.3% (one patient with renal failure). Values for MTX clearance (CLMTX) and 7‐OH‐MTX clearance (CL7‐OH‐MTX) were estimated at 8.85 and 2 L−1, respectively. Baseline creatinine clearance correlated with CLMTX and CL7‐OH‐MTX. Concurrent administration of benzimidazoles led to a 27% decrease in CLMTX and a 39% decrease in CL7‐OH‐MTX. Prior administration of nonsteroidal anti‐inflammatory drugs (NSAIDs) resulted in a 16% decrease in CLMTX and a 38% decrease in CL7‐OH‐MTX. Plasma MTX concentrations were significantly higher in patients also receiving benzimidazoles at 24 h (2.01 µmol L−1vs. 0.66 µmol L−1, P < 10−4) and at 48 h (0.25 µmol L−1vs. 0.12 µmol L−1, P < 10−4). 7‐OH‐MTX plasma concentrations were also significantly higher in patients with concurrent benzimidazoles as compared with patients without benzimidazoles at 24 h (4.47 µmol L−1vs. 2.52 µmol L−1, P = 0.0009) and at 48 h (1.11 µmol L−1vs. 0.72 µmol L−1, P = 0.031).Conclusions: In patients receiving HDMTX, concurrent administration of benzimidazoles was associated with a significant decrease of CLMTX and CL7‐OH‐MTX, resulting in significantly higher plasma concentrations of MTX and 7‐OH‐MTX. The data suggest that benzimidazole treatment should be seen as a relative contraindication for HDMTX.

13 September 2005 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
LWL Wuermli
L Wuermli
MJM Joerger
M Joerger
SHS Henz
S Henz
HSH-P Schmid
H-P Schmid
WRW F Riesen
W F Riesen
SGSilke Gillessen
Silke Gillessen

23 February 2005 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
MJM. Joerger
M. Joerger
AHA. D. R. Huitema
A. D. R. Huitema
PMP. L. Meenhorst
P. L. Meenhorst
JSJ. H. M. Schellens
J. H. M. Schellens
JBJ. H. Beijnen
J. H. Beijnen

24 June 2006 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MJM. Joerger
M. Joerger
TBT. M. Bosch
T. M. Bosch
VDV. D. Doodeman
V. D. Doodeman
JBJ. H. Beijnen
J. H. Beijnen
PSP. H. M. Smits
P. H. M. Smits
JSJ. H. M. Schellens
J. H. M. Schellens

8 August 2006 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
MJMarkus Joerger
Markus Joerger
AHA. D. R. Huitema
A. D. R. Huitema
WBW. Boogerd
W. Boogerd
JSJ. J. Van Der Sande
J. J. Van Der Sande
JSJ. H. M. Schellens
J. H. M. Schellens
JBJ. H. Beijnen
J. H. Beijnen
Phenytoin dosing is critical in cancer patients as to decreased absorption secondary to chemotherapy‐induced gastrointestinal toxicity, increased phenytoin metabolism in the liver secondary to chemotherapy, extreme patient profile that falls outside the predicted pharmacokinetic population, frequent hypoalbuminaemia and polydrug treatment. A retrospective study to assess the variability of free phenytoin and the free fraction of phenytoin, as well as the influence of comedication on these parameters was performed in cancer patients by using a population approach. Two hundred fifty‐eight data pairs of total phenytoin and free phenytoin were analysed from 155 cancer patients on stable phenytoin using non‐linear mixed‐effect modeling (NONMEM). Total and free phenytoin were determined using a fluorescence polarization immunoassay. An extensive model building procedure was subsequently used for covariate testing on the free fraction of phenytoin. Mean total phenytoin concentration was 11.7 mg/l, free phenytoin 1.25 mg/l and phenytoin free fraction 0.107. Free phenytoin was 2 mg/l on 37 occasions (14.3%). Total and free phenytoin were significantly correlated (rS=0.827, P<0.01). The free fraction of phenytoin was independent of time after drug intake. Serum albumin concentrations and comedication with valproic acid or carbamazepine were identified by NONMEM as significant determinants of phenytoin free fraction. Co‐medication with valproic acid and carbamazepine led to a 52.5% and 38.5% increase of the free fraction of phenytoin, respectively, and a 10 g/l decrease of serum albumin to a 15.1% increase of the free fraction of phenytoin. Phenytoin pharmacokinetics could reliably be estimated from oral doses and steady‐state concentrations of protein‐bound and free phenytoin. The variability in the free fraction of phenytoin could partly be explained by the influence of albumin concentrations and antiepileptic comedication. Significant alterations of the free fraction of phenytoin and free phenytoin by co‐administration of valproic acid or carbamazepine suggest therapeutic drug monitoring of free phenytoin to be of potential benefit in cancer patients.

1 January 2004 in Methods and Findings in Experimental and Clinical Pharmacology
Verified
Journal Article
Closed access
MJM. Joerger
M. Joerger
JSJ.H. Schellens
J.H. Schellens
JBJ.H. Beijnen
J.H. Beijnen
Therapeutic drug monitoring (TDM) or the measurement of drug concentrations in plasma, serum or blood, aims to improve clinical activity, avoid toxicity, and reduce the costs of drug treatment. Specific conditions for TDM to be reasonably applied include the availability of a validated assay, a considerable interindividual pharmacokinetic variability, a high correlation between drug concentration and toxicity, and a narrow therapeutic index. Cancer patients are especially prone to drug-drug interactions due to significant comedication, impaired liver and kidney function and hypoalbuminemia with altered drug binding. This article discusses TDM for various broadly used non-anticancer drugs in cancer patients and gives specific recommendations. Selected drugs covered in this article include those regularly used in febrile neutropenic patients such as the glycopeptide antibiotics, aminoglycosides, the antifungal agents, including flucytosine and azole compounds, the anticonvulsants phenytoin, carbamazepine and valproate, the tricyclic antidepressants, selective-serotonin-reuptake inhibitors, lithium, morphine, digitalis glycosides and the immunosupressants cyclosporin A, tacrolimus, sirolimus and mycophenolate mofetil, crucial compounds in the setting of bone marrow transplantation. In all cases, treating physicians have to consider the variability in patient age, disease stage, comedication, organ function and protein level to weigh the pros and cons of TDM in the individual cancer patient.